Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value

Respiratory syncytial virus (RSV) infection is the most common cause of lower respiratory tract infection and the leading cause of hospitalization among young children, incurring high annual costs among US children under the age of 5 years. Palivizumab has been found to be effective in reducing hosp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Olchanski, Natalia, Hansen, Ryan N, Pope, Elle, D’Cruz, Brittany, Fergie, Jaime, Goldstein, Mitchell, Krilov, Leonard R, McLaurin, Kimmie K, Nabrit-Stephens, Barbara, Oster, Gerald, Schaecher, Kenneth, Shaya, Fadia T, Neumann, Peter J, Sullivan, Sean D
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833316/
https://ncbi.nlm.nih.gov/pubmed/29516023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy031
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados